Treating hepatitis C-positive patients who underwent a liver transplant with a combination of three drugs -- pegylated interferon, ribavirin and telaprevir -- increased sustained viral response rates even for difficult cases, but adverse events were also common, according to findings presented at a liver meeting. Among the adverse events were the need for transfusions to address blood cell deficiencies. The study evaluated data from six U.S. centers.
HCV drug combo linked to side effects after liver transplant
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||